FY2025 · ended Dec 31, 2025 · Revenue $17.26B, +4.3% YoY · Filed Feb 3, 2026
Teva Pharmaceutical Industries Limited (TEVA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $17.3 billion and net income of $1.4 billion. Free cash flow was $1.1 billion. As of Sep 30, 2026 it held $4.1 billion in cash and investments and $4.3 billion in total debt.
Revenue (TTM)
$17.23B
+2.7% vs year-ago TTM
Net income (TTM)
$506.00M
-29.0% vs year-ago TTM
Operating cash flow (TTM)
$1.77B
+66.0% vs year-ago TTM
Free cash flow (TTM)
$1.24B
+113.7% vs year-ago TTM
EPS (TTM)
$0.43
-30.5% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
1.15B
+1.4% vs prior year
Net cash
$-219.00M
as of Sep 30, 2026
Operating margin
8.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TEVA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv
- SEC filer status
- Large accelerated filer
- SEC CIK
- 818686
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED (until Jan 16, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B |
| Operating income | $2.2B | -$303.0M | $433.0M | -$2.2B | $1.7B |
| Net income | $1.4B | -$1.6B | -$559.0M | -$2.4B | $417.0M |
| Diluted EPS | $1.21 | -$1.45 | -$0.50 | -$2.20 | $0.38 |
| Operating cash flow | $1.6B | $1.2B | $1.4B | $1.6B | $798.0M |
| Free cash flow | $1.1B | $749.0M | $842.0M | $1.0B | $236.0M |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B | $47.7B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B | $36.4B |
| Stockholders' equity | $7.9B | $5.4B | $7.5B | $7.8B | $10.3B |
| Cash and investments | $3.6B | $3.3B | $3.2B | $2.8B | $2.2B |
| Total debt | $2.2B | $2.2B | $2.1B | $2.5B | $2.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 11, 2026 | Sep 9, 2026 |
All 1001 Teva Pharmaceutical Industries Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.